Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-CAP
NCT07537413Phase 4Not yet recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ceftriaxone in community acquired pneumonia (CAP) (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Antibiotic escalation at 5 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ceftriaxone
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT07537413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537413.